Katie Kelley
Professor
Medicine
School of Medicine

Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.

• Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
  Future oncology (London, England) 2023 Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau…
• Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.
  Clinical pharmacology and therapeutics 2023 Song X, Kelley RK, Green M, Standifer N, Lim K, Zhou D, Dunyak J, Negro A, Kurland JF, Ren S, Khan AA, Gibbs M, Abou-Alfa GK
• Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
  Journal of the National Cancer Institute 2023 Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C…
• Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
  Cell reports. Medicine 2023 Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, …
• Polyunsaturated Fatty Acid-Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism.
  Cancer research 2023 Munson PV, Adamik J, Hartmann FJ, Favaro PMB, Ho D, Bendall SC, Combes AJ, Krummel MF, Zhang K, Kelley RK, Butterfield LH
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
  Lancet (London, England) 2023 Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel …
• Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Song X, Kelley RK, Khan AA, Standifer N, Zhou D, Lim K, Krishna R, Liu L, Wang K, McCoon P, Negro A, He P, Gibbs M, Kurland JF, Abou-Alfa GK
• Immunology and immunotherapy of cholangiocarcinoma.
  Nature reviews. Gastroenterology & hepatology 2023 Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW
• Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
  The New England journal of medicine 2023 Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, …
• Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review.
  Liver cancer 2023 Vogel A, Kelley RK, Johnson P, Merle P, Yau T, Kudo M, Meyer T, Rimassa L
• The evolving role of combination systemic therapies in hepatocellular carcinoma.
  Clinical advances in hematology & oncology : H&O 2022 Kelley RK
• What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.
  BMJ open 2022 McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, Shroff R, Moehler M, Lowery M, Bekaii-Saab T, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J
• The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma.
  Gastroenterology & hepatology 2022 Kelley RK
• Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis.
  Cell reports 2022 Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L
• Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B
• Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
  The Lancet. Oncology 2022 Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, …
• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
  NEJM evidence 2022 Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, …
• Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.
  Nature cancer 2022 Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A
• Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
  European journal of cancer (Oxford, England : 1990) 2022 Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK
• Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
  BMC cancer 2022 El-Khoueiry AB, Meyer T, Cheng AL, Rimassa L, Sen S, Milwee S, Kelley RK, Abou-Alfa GK
• Biliary cancer brain metastases: a multi-institution case series with case reports.
  Journal of gastrointestinal oncology 2022 Falkson SR, Zhang K, Bhambhvani HP, Wild JL, Griffin A, Kelley RK, Gephart MH
• Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
  The Journal of molecular diagnostics : JMD 2022 Silverman IM, Li M, Murugesan K, Krook MA, Javle MM, Kelley RK, Borad MJ, Roychowdhury S, Meng W, Yilmazel B, Milbury C, Shewale S, Feliz L, Burn TC, Albacker LA
• Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
  American journal of clinical oncology 2022 Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH
• Discovering dominant tumor immune archetypes in a pan-cancer census.
  Cell 2021 Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, …
• Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
  The Lancet. Oncology 2021 Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El…
• Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
  Liver cancer 2021 Rimassa L, Kelley RK, Meyer T, Ryoo BY, Merle P, Park JW, Blanc JF, Lim HY, Tran A, Chan YW, McAdam P, Wang E, Cheng AL, El-Khoueiry AB, Abou-Alfa GK
• BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
  Journal of hepatology 2021 Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J
• Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
  British journal of cancer 2021 Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK
• Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
  Cancer discovery 2021 Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L
• Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.
  Liver cancer 2021 Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhang K, Bocobo AG, Benson AB, Venook AP, Gordan JD
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
  Journal for immunotherapy of cancer 2021 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson …
• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
  The lancet. Gastroenterology & hepatology 2021 Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer …
• Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M,…
• Hepatocellular Carcinoma - Origins and Outcomes.
  The New England journal of medicine 2021 Kelley RK, Greten TF
• Cabozantinib: An evolving therapy for hepatocellular carcinoma.
  Cancer treatment reviews 2021 El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK
• Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
  Cancer medicine 2021 Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK
• Hepatocellular carcinoma.
  Nature reviews. Disease primers 2021 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS
• Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
  ESMO open 2020 Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK
• Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK
• Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
  The oncologist 2020 Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa …
• Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
  Future oncology (London, England) 2020 Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L
• Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
  Advances in therapy 2020 Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK
• Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer.
  The New England journal of medicine 2020 Kelley RK
• Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
  The Lancet. Oncology 2020 Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-…
• Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
  International journal of cancer 2020 Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T
• Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.
  Clinical liver disease 2020 Huppert LA, Gordan JD, Kelley RK
• Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
  PloS one 2020 Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S
• Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020 Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA
• Systemic therapies for intrahepatic cholangiocarcinoma.
  Journal of hepatology 2020 Kelley RK, Bridgewater J, Gores GJ, Zhu AX
• Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.
  Nature reviews. Gastroenterology & hepatology 2020 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X
• Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
  Journal of gastrointestinal cancer 2019 Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K
• Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
  JAMA oncology 2019 Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-…
• Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
  Journal for immunotherapy of cancer 2019 Keenan BP, Fong L, Kelley RK
• Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
  Cancer 2019 Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK
• Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
  Journal of gastrointestinal oncology 2019 Boscoe AN, Rolland C, Kelley RK
• Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-…
• Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
  Liver international : official journal of the International Association for the Study of the Liver 2019 Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G
• Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
  Cancer 2019 Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK
• TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
  Cancer discovery 2019 Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, …
• Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
  The Journal of pathology 2019 Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, Bowman S, Talevich E, Ferrell LD, Kakar S, Krings G
• Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma.
  Clinical nuclear medicine 2019 Perez PM, Flavell RR, Kelley RK, Umetsu S, Behr SC
• An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
  The oncologist 2018 El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK
• Emerging Role for Systemic Therapy in Earlier Stages of HCC.
  International journal of radiation oncology, biology, physics 2018 Kelley RK
• Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype.
  JCO precision oncology 2018 Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M
• Cabozantinib in Hepatocellular Carcinoma.
  The New England journal of medicine 2018 Abou-Alfa GK, Borgman-Hagey AE, Kelley RK
• Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
  The New England journal of medicine 2018 Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, …
• Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
  The oncologist 2018 Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK
• Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana…
• Cholangiocarcinoma - evolving concepts and therapeutic strategies.
  Nature reviews. Clinical oncology 2017 Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2017 Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D
• Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
  The oncologist 2017 Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M
• NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, …
• Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E
• Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA
• Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
  Molecular imaging 2017 Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ
• Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
  Journal of gastrointestinal oncology 2016 Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, …
• Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
  Journal of gastrointestinal oncology 2016 Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP
• Biliary cancer: Utility of next-generation sequencing for clinical management.
  Cancer 2016 Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J
• A phase II study of axitinib in advanced neuroendocrine tumors.
  Endocrine-related cancer 2016 Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK
• A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
  Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
• A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL
• Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
  The Lancet. Oncology 2015 Kelley RK
• A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM
• A 46-Year-Old Asian Woman With Liver Mass.
  Seminars in oncology 2015 Morris GJ, Covey AM, D'Angelica M, Chang DT, Yen Y, Kelley RK, Greenberg H, Tsioulias G
• Biliary Tract Cancers: Finding Better Ways to Lump and Split.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Kelley RK, Bardeesy N
• A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
  Cancer 2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN
• Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
  Cancer discovery 2015 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA
• Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
  Journal of gastrointestinal cancer 2015 Parks AL, McWhirter RM, Evason K, Kelley RK
• Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
  BMC cancer 2015 Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW
• Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Trosman JR, Weldon CB, Kelley RK, Phillips KA
• A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
  Anticancer research 2014 Cinar P, Calkins SM, Venook AP, Kelley RK
• Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
  International journal of cancer 2014 Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ
• Hepatobiliary cancers, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, …
• Genomic sequencing: assessing the health care system, policy, and big-data implications.
  Health affairs (Project Hope) 2014 Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB
• 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
  Journal of gastrointestinal cancer 2014 Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP
• A review of hepatocellular carcinoma (HCC) staging systems.
  Chinese clinical oncology 2013 Subramaniam S, Kelley RK, Venook AP
• A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
  British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK
• Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Kelley RK
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
  Annals of oncology : official journal of the European Society for Medical Oncology 2013 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP
• Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
  Gastrointestinal cancer research : GCR 2013 Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook…
• Novel therapeutics in hepatocellular carcinoma: how can we make progress?
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013 Kelley RK, Venook AP
• Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
  American journal of clinical oncology 2012 Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA
• Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.
  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012 Kelley RK, Hirose R, Venook AP
• Predictive biomarkers in advance of a companion drug: ahead of their time?
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Kelley RK, Atreya C, Venook AP, Febbo PG
• Multidisciplinary management of hepatocellular carcinoma.
  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N
• Biomarker use in colorectal cancer therapy.
  Journal of the National Comprehensive Cancer Network : JNCCN 2011 Kelley RK, Wang G, Venook AP
• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2011 Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML
• Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy?
  Journal of hepatology 2011 Kelley RK, Yao F
• Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
  Clinical colorectal cancer 2011 Kelley RK, Venook AP
• "And what other medications are you taking?".
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP
• Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2011 Kelley RK, Van Bebber SL, Phillips KA, Venook AP
• KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic.
  PLoS currents 2010 Wang G, Kelley RK
• Nonadherence to imatinib during an economic downturn.
  The New England journal of medicine 2010 Kelley RK, Venook AP
• A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
  Cancer chemotherapy and pharmacology 2010 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA
• Drug development in advanced colorectal cancer: challenges and opportunities.
  Current oncology reports 2009 Kelley R, Venook AP
• Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Kelley RK, Venook AP
• Erlotinib in the treatment of advanced pancreatic cancer.
  Biologics : targets & therapy 2008 Kelley RK, Ko AH